Journal Report

EXPERT REVIEW OF VACCINES

Download PDF
Journal Information
Journal Title
EXPERT REVIEW OF VACCINES
Publisher
TAYLOR & FRANCIS LTD
ISSN
1476-0584
E-ISSN
1744-8395
Database
Clarivate
Domain
Health Sciences, Life Sciences, Social Sciences
Classification History
Year A+ A B C
2026 ✓ ✓
2025 ✓ ✓
2024 ✓ ✓
2023 ✓ ✓
2021/2022 ✓ ✓
2020 ✓ ✓
2019 ✓ ✓
2018 ✓
A journal may have more than one classification in the same year. All recorded classifications are displayed.
Recent Articles
Testing a 24-valent pneumococcal investigational vaccine in older adults aged 65 to 85 years: safety, reactogenicity, and immunogenicity. A plain language summary of two publications
Michele Pellegrini, Naveen Karkada, Dorota Borys et al.
2026-11-12 Vol. 25 Issue 1
DOI: 10.1080/14760584.2026.2749190
Respiratory syncytial virus (RSV) vaccine recommendations for adults: a review of available global, regional, and country level recommendations
Otavio Cintra, Abhay Phansalkar, Maria Laucho-Contreras et al.
2026-11-5 Vol. 25 Issue 1
DOI: 10.1080/14760584.2026.2755658
Association of the publicly funded two-dose varicella vaccine policy with varicella incidence in Shanghai: an interrupted time series study
Qiangsong Wu, Jingyi Ye, Kuan Wan et al.
2026-11-5 Vol. 25 Issue 1
DOI: 10.1080/14760584.2026.2756695
Effectiveness and implementation of electronic decision support for adult vaccination in primary care: a mixed-methods quasi-experimental evaluation
Yuxing Wang, Yinxing Lu, Jianing Dai et al.
2026-11-4 Vol. 25 Issue 1
DOI: 10.1080/14760584.2026.2743405
Modeling the cost-effectiveness of NVX-CoV2705 and the public health impact of vaccination for the prevention of seasonal COVID-19 in the US
Lindsey Fox, Kyle Paret, Maureen P. Neary et al.
2026-11-3 Vol. 25 Issue 1
DOI: 10.1080/14760584.2026.2748732
Progress toward HIV-1 subtype C vaccines: understanding antiviral immune mechanisms and viral adaptation
Anna-Lise Williamson, Edward P. Rybicki
2026-11-2 Vol. 25 Issue 1
DOI: 10.1080/14760584.2026.2753910
Safety and immunogenicity of the 24-valent pneumococcal conjugate vaccine in healthy Chinese adults: two single-center, randomized, double-blind Phase 1 and Phase 2 trials
Kangning Wang, Jialei Hu, Huagen Chen et al.
2026-10-22 Vol. 25 Issue 1
DOI: 10.1080/14760584.2026.2746803
The socioeconomic value of adult respiratory vaccination in Australia: a benefit-cost analysis
Matthew Napier, Angus Macfarlane, Ellie Tunnicliffe et al.
2026-10-17 Vol. 25 Issue 1
DOI: 10.1080/14760584.2026.2748741
Virus-like particle vaccines: from antigen architecture to antigen presentation and adaptive immune responses
Zihan Zhang, Huiwen Zheng, Longding Liu
2026-10-14 Vol. 25 Issue 1
DOI: 10.1080/14760584.2026.2746121
Cost-effectiveness analysis of pneumococcal conjugate vaccines, PCV21 vs PCV20, in adults aged  ≥60 years in Germany
Muloongo Simuzingili, Peter P. Mueller, Lisa M. Oexle et al.
2026-10-5 Vol. 25 Issue 1
DOI: 10.1080/14760584.2026.2739087
Articles retrieved from Crossref.
Green Journals | https://www.green-journals.com | info@green-journals.com
Printed: November 13, 2026 15:47